Egeler R M, Neglia J P, Aricò M, Favara B E, Heitger A, Nesbit M E, Nicholson H S
Southern Alberta Children's Cancer Program, Alberta Children's Hospital, Tom Baker Cancer Centre, University of Calgary, Canada.
Hematol Oncol Clin North Am. 1998 Apr;12(2):369-78. doi: 10.1016/s0889-8588(05)70516-5.
The frequency of Langerhans cell histiocytosis (LCH) and a malignant neoplasm occurring in the same individual appears to be greater than previously recognized. To define the occurrence and the pattern of these events, a Study Group of the Histiocyte Society initiated a registry of patients in whom this association occurred synchronously or asynchronously. Evaluation of 54 patients detected two patterns of associations between LCH and other disorders. First, it is possible that therapy of LCH promotes a secondary malignancy. Second, it is possible that a genetic predisposition, with or without the immunosuppression associated therapy for the malignancy, plays a role in the development and expression of disseminated LCH. Data collected by the LCH-Malignancy Study Group may provide insights into the etiology and pathophysiology of LCH.
朗格汉斯细胞组织细胞增多症（LCH）与同一患者体内发生的恶性肿瘤同时出现的频率似乎比之前认为的更高。为了明确这些情况的发生及模式，组织细胞协会研究小组启动了一项针对LCH与其他疾病同步或异步关联患者的登记工作。对54例患者的评估发现了LCH与其他疾病之间的两种关联模式。第一，LCH的治疗可能会促使继发性恶性肿瘤的发生。第二，遗传易感性，无论是否伴有恶性肿瘤相关的免疫抑制治疗，都可能在播散性LCH的发生和表现中发挥作用。LCH-恶性肿瘤研究小组收集的数据可能为LCH的病因学和病理生理学提供见解。
